INV-347 for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines the long-term safety of a drug called INV-347, previously tested for obesity treatment. Participants will not receive the drug again; instead, researchers will monitor how their bodies continue to process it over time. The study targets individuals who participated in a past trial and still have detectable levels of INV-347 in their blood. As a Phase 1 trial, the research focuses on understanding how the treatment functions in people, providing valuable insights into its long-term effects.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the study team or your doctor.
Is there any evidence suggesting that INV-347 is likely to be safe for humans?
Research shows that INV-347 is in the early stages of human testing, meaning complete safety information is not yet available. These early tests primarily focus on safety, with researchers closely monitoring INV-347 for any side effects. Since participants have already taken the drug, researchers are particularly interested in any long-term safety issues.
As INV-347 remains in the early testing phase, its safety is under careful study. So far, no clear reports of serious side effects have emerged. Participants should understand that the main goal is to gather as much safety information as possible.12345Why are researchers excited about this trial?
Unlike the standard treatments for obesity, which often include lifestyle changes, medications like orlistat, or even surgical options, INV-347 is unique because it is designed to assess long-term safety after initial human exposure. Researchers are excited about INV-347 because it may offer a novel approach by maintaining measurable plasma exposure over time, which could potentially lead to sustained effects in managing obesity. This ongoing exposure might help in understanding the long-term impact and safety of the treatment, which is a crucial consideration for chronic conditions like obesity.
What evidence suggests that INV-347 might be an effective treatment for obesity?
Research has shown that INV-347 led to significant weight loss in earlier studies, with noticeable results in just 28 days. This drug blocks a specific receptor in the brain, helping to reduce appetite and support weight loss. Some participants reported mild to moderate side effects, such as anxiety. Although Novo Nordisk decided not to continue developing INV-347, the initial results for weight loss were promising. Those interested in this treatment should consider the potential benefits and possible side effects.26789
Who Is on the Research Team?
Clinical Transparency (dept. 2834)
Principal Investigator
Novo Nordisk A/S
Are You a Good Fit for This Trial?
This trial is for individuals who were previously given the drug INV-347 in an earlier study (INV-CL-108) and are being monitored for safety. The focus is on those with obesity, but no new participants will be dosed.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Safety Follow-up
Participants are monitored for safety and blood levels of INV-347 without receiving any study drug
End-of-study visit
Final assessment of participants' safety and any adverse events
What Are the Treatments Tested in This Trial?
Interventions
- INV-347
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novo Nordisk A/S
Lead Sponsor
Lars Fruergaard Jørgensen
Novo Nordisk A/S
Chief Executive Officer since 2017
MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark
Martin Holst Lange
Novo Nordisk A/S
Chief Medical Officer since 2021
MD from University of Copenhagen